This Weekend's Barron's: The Biannual Big Money Poll ~ AIG Shares Could Double in Five years ~ Trinity Biotech's Stock Looks Healthy ~ The Best Oil Company You Never Heard Of ~ Assessing Pfizer's Future

This sneak preview offers highlights from this weekend's Barron's. Come back to Barrons.com on Saturday morning.

Thank You

Error.

An error has occurred and your email has not been sent.
Please try again.

April 26, 2014 3:37 a.m. ET

Tired BullBarron's latest Big Money poll finds U.S. money managers less gung-ho than they were six months ago -- but they still see room for stocks to rally 10% through mid-2015. They discuss their favorite -- and least favorite -- investment ideas.

The Best Advice: Keeping a Different Beat Financial advisor Scott Magnesen embraces an unflashy investment philosophy geared toward "Ma and Pa America." His advice: Buy and hold for 10 years or more, Barron's reports.

This week, Barron'sinterviews Doug Kass, president of Seabreeze Partners Management. He thinks the S&P is at least 12% overvalued, but is positioning to make money even in a selloff. He names some of his current Picks and Pans.

European Trader: Novartis and Glaxo's Mutually Beneficial Waltz A multipart deal between drug makers Novartis and GlaxoSmithKline could pay off for shareholders of both companies, Barron's reports. Novartis is buying GSK's oncology business, while GSK is acquiring most of Novartis' vaccines business, and they're combining their consumer health-care businesses.

Asian Trader: Asian Small-Caps Are Overlooked Asian stocks have mostly lagged their developed-market peers in the past 16 months. That has created some bargains, especially among smaller valuation companies that don't get much investor attention, Barron's reports.